{"classes":[{"categories":[{"measurements":[{"comment":"Not calculated for 1 participant.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"350.1861","value":"587.667"},{"groupId":"OG002","spread":"156.2679","value":"923.484"},{"comment":"Not calculated for 1 participant.","groupId":"OG003","spread":"NA","value":"NA"}]}],"title":"Day 1 (n=1, 3, 4, 1)"},{"categories":[{"measurements":[{"comment":"Not calculated for 2 participants.","groupId":"OG000","spread":"NA","value":"834.608"},{"groupId":"OG001","spread":"104.0256","value":"1083.998"},{"groupId":"OG002","spread":"262.7420","value":"1831.324"},{"comment":"Not calculated for 1 participant.","groupId":"OG003","spread":"NA","value":"NA"}]}],"title":"Day 15 (n=2, 3, 3, 1)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"AUC(0-168) is a measure of the area under the plasma concentration-time curve from time 0 to 168 hours postdose for Ixazomib.","dispersionType":"Standard Deviation","groups":[{"description":"In phase 1, ixazomib 1.68 mg/m\\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 1.68 mg/m\\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone"},{"description":"In phase 1, ixazomib 2.23 mg/m\\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.23 mg/m\\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone"},{"description":"In phase 1, ixazomib 2.97 mg/m\\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.97 mg/m\\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.","id":"OG002","title":"Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone"},{"description":"In phase 1, ixazomib 3.95 mg/m\\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 3.95 mg/m\\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.","id":"OG003","title":"Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The Pharmacokinetic (PK) analysis population, defined as all patients enrolled in the phase 1 portion of the study who had sufficient dosing data and ixazomib concentration-time data to permit calculation of ixazomib pharmacokinetic parameters, with available data.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Days 1 and 15","title":"Phase 1: AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for Ixazomib","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}